These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 11504787)

  • 1. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.
    Zellweger T; Miyake H; Cooper S; Chi K; Conklin BS; Monia BP; Gleave ME
    J Pharmacol Exp Ther; 2001 Sep; 298(3):934-40. PubMed ID: 11504787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin.
    Zellweger T; Miyake H; July LV; Akbari M; Kiyama S; Gleave ME
    Neoplasia; 2001; 3(4):360-7. PubMed ID: 11571636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models.
    Springate CM; Jackson JK; Gleave ME; Burt HM
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):239-47. PubMed ID: 15864591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin.
    Zellweger T; Chi K; Miyake H; Adomat H; Kiyama S; Skov K; Gleave ME
    Clin Cancer Res; 2002 Oct; 8(10):3276-84. PubMed ID: 12374699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo.
    July LV; Beraldi E; So A; Fazli L; Evans K; English JC; Gleave ME
    Mol Cancer Ther; 2004 Mar; 3(3):223-32. PubMed ID: 15026542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
    Miyake H; Nelson C; Rennie PS; Gleave ME
    Cancer Res; 2000 May; 60(9):2547-54. PubMed ID: 10811138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.
    Gleave ME; Miyake H; Zellweger T; Chi K; July L; Nelson C; Rennie P
    Urology; 2001 Aug; 58(2 Suppl 1):39-49. PubMed ID: 11502446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
    Miyake H; Chi KN; Gleave ME
    Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.
    Gleave M; Miyake H
    World J Urol; 2005 Feb; 23(1):38-46. PubMed ID: 15770517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
    Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
    Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clusterin regulates drug-resistance in melanoma cells.
    Hoeller C; Pratscher B; Thallinger C; Winter D; Fink D; Kovacic B; Sexl V; Wacheck V; Gleave ME; Pehamberger H; Jansen B
    J Invest Dermatol; 2005 Jun; 124(6):1300-7. PubMed ID: 15955107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.
    Chi KN; Eisenhauer E; Fazli L; Jones EC; Goldenberg SL; Powers J; Tu D; Gleave ME
    J Natl Cancer Inst; 2005 Sep; 97(17):1287-96. PubMed ID: 16145049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression.
    Miyake H; Hara I; Kamidono S; Gleave ME; Eto H
    Oncol Rep; 2003; 10(2):469-73. PubMed ID: 12579291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model.
    Yamanaka K; Gleave M; Muramaki M; Hara I; Miyake H
    Oncol Rep; 2005 May; 13(5):885-90. PubMed ID: 15809754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.
    Rocchi P; So A; Kojima S; Signaevsky M; Beraldi E; Fazli L; Hurtado-Coll A; Yamanaka K; Gleave M
    Cancer Res; 2004 Sep; 64(18):6595-602. PubMed ID: 15374973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H; Yu D; Agrawal S; Zhang R
    Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
    Miyake H; Hara I; Kamidono S; Gleave ME
    Clin Cancer Res; 2001 Dec; 7(12):4245-52. PubMed ID: 11751526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity.
    Hayashi N; Koller E; Fazli L; Gleave ME
    Prostate; 2008 Sep; 68(12):1283-95. PubMed ID: 18512732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2.
    Rubenstein M; Tsui P; Guinan P
    Med Oncol; 2010 Sep; 27(3):592-9. PubMed ID: 19533419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spinal distribution and metabolism of 2'-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats.
    Butler M; Hayes CS; Chappell A; Murray SF; Yaksh TL; Hua XY
    Neuroscience; 2005; 131(3):705-15. PubMed ID: 15730875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.